Toni K. Choueiri, MD

Articles

Dr Choueiri on the Utility of Belzutifan/Cabozantinib in Advanced ccRCC

October 27th 2023

Toni K. Choueiri, MD, discusses findings from the phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced clear cell renal cell carcinoma.

Dr Choueiri on the Benefit of Ongoing Investigations in Metastatic RCC

October 7th 2023

Toni K. Choueiri, MD, discusses the benefit of ongoing investigations in metastatic, advanced renal cell carcinoma.

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

Dr. Choueiri on the FDA Approval of Adjuvant Pembrolizumab in RCC

November 19th 2021

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Choueiri on the Efficacy of Post-Nephrectomy, Adjuvant Pembrolizumab in RCC

June 4th 2021

Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.

Dr. Choueiri on the FDA Approval of Nivolumab/Cabozantinib in mRCC

January 22nd 2021

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

Dr. Choueiri on Expanding the Therapeutic Armamentarium in mRCC

August 3rd 2020

Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.

Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC

May 29th 2020

Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

February 15th 2020

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

December 4th 2019

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

December 5th 2018

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.

Dr. Choueiri on Impact of CABOSUN Results in Renal Cell Carcinoma

September 10th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

Dr. Choueiri on the Biology of the CABOSUN Trial for RCC

August 21st 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

Dr. Choueiri on Trials Investigating Combination Regimens for RCC

August 7th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCC

July 26th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the synergy between immunotherapy agents and VEGF inhibitors in renal cell carcinoma (RCC).

Dr. Choueiri on Avelumab Plus Axitinib in mRCC

June 8th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).

Dr. Choueiri on the Role of Traditional Agents in Kidney Cancer

February 27th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of traditional agents in the treatment of patients with kidney cancer.

Dr. Choueiri on Overall Findings of the CABOSUN Trial for RCC

February 4th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses overall findings of the phase II CABOSUN trial comparing cabozantanib (Cabometyx) versus sunitinib (Sutent) for patients with metastatic renal cell carcinoma.

Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

October 20th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.

Dr. Choueiri on CABOSUN Trial Results for RCC

October 13th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the results of the phase II CABOSUN trial, which compared cabozantinib (Cabometyx) with sunitinib (Sutent) in the frontline setting of patients with metastatic renal cell carcinoma (RCC).